Since the term tissue engineering was coined in 1993, the fields of tissue engineering, regenerative medicine, and cell therapy have greatly matured from benchtop ideas to commercially available products that are widely used in the clinic. We broadly define “tissue engineering” as the culmination of engineering and biology to advance the restoration or improvement of tissue function.
Artificial organs, biomaterials, and cell therapies that leverage autologous or donor cells have been utilized for regenerative purposes. Currently, the terms “tissue engineering” and “regenerative medicine” bring up 1.2 and 0.6 million results on Google Scholar, respectively. This indicates how much the field has grown in only 25 years.
This report seeks to provide an update of the tissue engineering industry from 2011 to 2018. Public tissue engineering companies with a presence in the United States were the focus of this report due to the publicly accessible financial data that they provide. The report identifies 49 companies. (A partial list, which shows 25 companies, appears in the Table.) Twenty-one of the companies were in the commercial phase of development and had products on the market. These 21 companies made an estimated $9 billion in sales of tissue engineering–related products in 2017. Based on previous reports and market trends, the field of tissue engineering is forecasted to continue to build revenue for the years to come.
Yu Seon Kim and Mollie M. Smoak are graduate students; Anthony J. Melchiorri, PhD, is associate director, Biomaterials Lab; and Antonios G. Mikos, PhD, is Louis Calder Professor of Bioengineering and professor of chemical and biomolecular engineering at Rice University.
*Adapted and abridged from “An Overview of the Tissue Engineering Market in the United States from 2011 to 2018,” Tissue Engineering, Part A, September 4, 2018, published by Mary Ann Liebert, Inc.